Spiderwort Biotechnologies Inc. Announces Status of Biocompatibility Testing for CelluJuve®
Cellulose dermal filler achieves critical biocompatibility milestones, paving the way for clinical trials
OTTAWA, ON, April 29, 2025 /CNW/ - Spiderwort Biotechnologies Inc., a pioneering biotechnology company focused on cellulose-based regenerative medicine, today announced the completion of ISO 10993 biocompatibility testing and human skin safety testing for its future product family, CelluJuve ®, a series of next-generation dermal fillers.
CelluJuve ® is a cellulose-based dermal filler solution being developed to provide structural support for soft tissue augmentation and rejuvenation.
"The successful completion of ISO 10993 testing is a pivotal moment for Spiderwort in our advancement toward clinical trials," said Dr. Charles M. Cuerrier, CEO of Spiderwort Biotechnologies Inc. "These results help validate our innovative biotechnology platform that transforms cellulose into a medical-grade product."
ISO 10993 testing is a key prerequisite for entering human clinical trials. As a complement to ISO 10993 requirements, Spiderwort Biotechnologies Inc. performed skin prick and patch testing in human subjects to further validate biocompatibility. The comprehensive testing demonstrated in non-clinical models that CelluJuve ® is:
Non-toxic, non-sensitizing, and non-mutagenic
Classified as a non-irritant and non-sensitizing for a diverse range of human skin types, as verified through additional human skin prick and patch testing
Highly biocompatible and stable
"These results represent years of technical development in transforming cellulose-based materials into medical-grade solutions," Dr. Andrew Pelling, Chief Science Officer at Spiderwort Biotechnologies Inc., "Our team has fundamentally reimagined what's possible in biomaterials, proving we can leverage plant structures in ways that are not only compatible with human tissue but offer unique advantages over traditional options. This milestone helps validate our approach and moves us closer to redefining what's possible in regenerative medicine."
Throughout the assessments, Spiderwort Biotechnologies Inc. placed significant emphasis on ensuring diversity in its testing protocols. This approach ensures CelluJuve ® has the potential to benefit all skin tones, reflecting Spiderwort Biotechnologies Inc.'s commitment to inclusive development practices.
"As a clinician focused on aesthetic outcomes and patient safety, I'm impressed with CelluJuve's biocompatibility profile," Dr. Jason Bloom, MD, FACS, member of Spiderwort's Clinical Advisory Board and renowned facial plastic surgeon, "The non-irritant classification and human testing results suggest CelluJuve ® could offer a compelling alternative in the dermal filler space. Physicians and patients increasingly seek new and innovative options with favorable safety profiles, and these test results position CelluJuve ® to potentially address that growing demand while offering unique structural properties for tissue augmentation and rejuvenation."
Construction of Spiderwort's state-of-the-art ISO 5 cleanroom facility, announced earlier this year, has been instrumental in achieving these results, reinforcing the company's ability to transform raw cellulose materials into medical devices that meet the stringent standards necessary for human use.
CelluJuve ® is a device under development. It is not approved by Health Canada or the U.S. Food and Drug Administration, and it is not available for sale. The safety and effectiveness of CelluJuve ® in humans has not been established. For more information about Spiderwort Biotechnologies and CelluJuve ®, please visit https://spiderwortbio.com/product/cellujuve/.
About Spiderwort Biotechnologies Inc.
Spiderwort is transforming biotechnology with a platform of cellulose-based biomaterials that serve as the scaffolds for the regenerative medicine of the future. Spiderwort's biomaterials have shown promise in the treatment of spinal cord injuries and soft tissue regeneration. Spun out as a startup from the Pelling Lab, Spiderwort is led by CEO Charles M. Cuerrier and inspired by the work of CSO and TED Fellow Andrew E. Pelling. Learn more at spiderwortbio.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
9 hours ago
- Cision Canada
Yardi launches Aspire Platinum package with cutting-edge AI tools
The learning management platform upgrades its offering to include advanced features for enhanced customization, engagement and integration capabilities SANTA BARBARA, Calif., June 6, 2025 /CNW/ -- Yardi ® is proud to announce the launch of Aspire Platinum, the newest and most advanced tier of its Yardi® Aspire learning management system, designed for property management companies that need advanced tools to scale training, improve engagement and stay ahead of change. Among the standout features in Aspire Platinum is Aspire AI, a powerful set of content creation tools that help training teams move faster and do more. With just a few clicks, teams can generate interactive courses, embed scenario-based challenges, build assessments, translate it all to other languages and more. "Aspire Platinum is for companies that want the latest technology to support strong, effective training programs that solve real business challenges." said Patty Evans, industry principal for Yardi Aspire. "It's built to help training teams save time, reach more people and make a bigger impact." Platinum also includes tools that make training more interactive and efficient, such as: Surveys and live polling for real-time feedback and engagement SCORM course compatibility for importing external content Embedded esignature workflows for policies, checklists and acknowledgments Microsoft Teams chat integration for seamless collaboration and communication Aspire Platinum builds on the robust foundation of the comprehensive Aspire Plus package, trusted by property management companies of all sizes. Aspire Plus features a customizable course catalog, event and mentorship management, embedded authoring tools, company resource library, mobile app and a sleek, modern, personalized learning experience. "We designed Aspire Platinum to give companies more flexibility, faster content creation and better ways to engage their teams," added Evans. "It offers the sophistication and efficiency that today's property management leaders need, without making things more complicated." Aspire Platinum helps organizations modernize their learning strategy, support compliance and build high-performing teams in a way that's personalized, scalable and easy to manage. Find out which Aspire package is right for you, or book a demo to see it in action. About Yardi
Cision Canada
17 hours ago
- Cision Canada
/C O R R E C T I O N from Source -- Ario Khoshbin/
In the news release, Ario Khoshbin Files Oppression Lawsuit Following Removal as CEO of Prollenium, issued 16-May-2025 by Ario Khoshbin over PR Newswire, we are advised by the source that the second paragraph has been updated. The complete, corrected release follows: Ario Khoshbin Files Oppression Lawsuit Following Removal as CEO of Prollenium TORONTO, May 16, 2025 /CNW/ - Ario Khoshbin, founder and former Chief Executive Officer of Prollenium Medical Technologies Inc., has commenced legal proceedings in the Ontario Superior Court of Justice Commercial List, against ArchiMed SAS, Panacea Holdings Inc., Prollenium Medical Technologies Inc., and related entities. The Statement of Claim includes allegations of shareholder oppression under the Canada Business Corporations Act, as well as breach of contract and wrongful dismissal. Mr. Khoshbin founded Prollenium in 2002 while still a university student. Over the next two decades, he developed the company into a global aesthetics business, with proprietary R&D, advanced manufacturing facilities, and distribution in over 80 countries. Prollenium is the only company manufacturing hyaluronic acid dermal fillers in North America and is the manufacturer of the globally recognized dermal filler brand Revanesse®. In 2021, Mr. Khoshbin sold a majority stake in the company to ArchiMed, a European private equity firm, while continuing in his role as CEO and remaining a significant minority shareholder and board director. In the Statement of Claim, Mr. Khoshbin alleges that following the acquisition, ArchiMed began operating the company in a manner that sidelined minority shareholders, focused on short-term financial objectives, and diverged from prior representations about long-term growth and innovation. The claim states that Mr. Khoshbin was gradually excluded from key governance decisions and was ultimately removed from his role without cause. The Statement of Claim alleges that Mr. Khoshbin did not voluntarily resign but was instead removed by board vote on April 4, 2025, contrary to public statements made by the Defendants at the time of Mr. Khoshbin's termination. The claim further alleges that Mr. Khoshbin's termination was not preceded by any formal performance process, and that he had expressed willingness to support an orderly transition. It also alleges that ArchiMed had pre-selected Walter Geiger, an operating partner at ARCHIMED SAS based in Zurich, as interim CEO prior to the meeting, and that he did not hold a Canadian work permit at the time of his appointment. The claim states that Mr. Geiger has been performing his duties from Prollenium's Richmond Hill facility. Following his removal, Mr. Khoshbin formally stepped down from the Board of Directors of Panacea Holdings. He continues to hold a 30% indirect ownership interest in the company and owns both of its core manufacturing facilities in Aurora and Richmond Hill, Ontario. "The opportunity to build Prollenium into what it is today has been the defining journey of my professional life," said Mr. Khoshbin. "My departure as CEO was abrupt and not by choice, but my commitment to the company's mission, legacy, its employees, and its long-term success remains unwavering." The Statement of Claim seeks various remedies, including a court-ordered buyout of Mr. Khoshbin's shares at fair market value, damages for wrongful dismissal, breach of contract, and reputational harm. The allegations have not yet been tested in court.
Cision Canada
a day ago
- Cision Canada
Maple Leaf Foods Releases 2024 Integrated Report Highlighting Sustainability and Strategic Achievements Français
Purpose-driven consumer packaged goods protein company continues unwavering commitment to sustainability, shared value, and strategic growth MISSISSAUGA, ON, June 5, 2025 /CNW/ - (TSX: MFI) Maple Leaf Foods ("the Company") released today its annual Integrated Report, bringing together an update on its 2024 financial performance and future outlook, as well as a holistic view of the Company's key initiatives, emphasizing its continued commitment to sustainability, shared value, and strategic growth. "2024 was a year of meaningful financial and strategic progress for Maple Leaf Foods," said Curtis Frank, President and Chief Executive Officer, Maple Leaf Foods. "Fueled by the strength of our leading brands, the resilience of our growth strategies and the financial benefits flowing from our large-scale capital investments, we exited the year with strong momentum on our journey to transform Maple Leaf Foods into a purpose driven, protein-focused, brand-led, consumer packaged goods powerhouse." "We also refreshed our Strategic Blueprint and evolved the strategies that will guide us toward achieving our Vision, to be the most sustainable protein company on Earth," Frank added. "I am incredibly proud of the strides we've made and our many remarkable achievements which are helping us create shared value for our stakeholders." Company Commitments The report highlights Maple Leaf Foods' leadership in sustainability, animal care, food and people safety, and its contributions to essential efforts to reduce food insecurity. The Company tracks progress against its goals based on key pillars: Making Better Food, Taking Care of Our People, Communities, and Animals, and Nurturing a Better Planet. Key Highlights: Making Better Food: Maple Leaf Foods continues to lead the market with high-quality, innovative products. Its flagship brands Schneiders ® and Maple Leaf ® achieved the #1 and #2 lead in Packaged Meats in Canada, while Mina ® earned the top spot as the #1 Halal brand in fresh poultry in Canada, and Greenfield Natural Meat Co. ® the #1 brand in Sustainable Packaged Meats in Canada. In 2024, the Company launched 50 new products across its brands, including Schneiders Breakfast Sandwiches and Schneiders Breakfast Bites. The new Schneiders ® breakfast products are part of Maple Leaf Foods' broader innovation strategy as a consumer-packaged goods-driven business to create new, sustainably produced products that meet the evolving needs and preferences of consumers. Taking Better Care for Our People: Maple Leaf Foods completed 11 social compliance audits in 2024, and took the next steps in advancing its enhanced social compliance program. The Company also successfully maintained a Total Recordable Incident Rate (TRIR) of 0.37, which is a 94% improvement since 2012. Taking Better Care for Our Communities: The Maple Leaf Centre for Food Security ("the Centre") has committed $13.3 million to 40 initiatives over the last eight years, addressing food insecurity across Canada. In 2024, Maple Leaf Foods donated $4 million in food products in Canada and the United States. Team Members across the Company volunteered in more than 33 communities, supporting local food banks, healthcare institutions, community centres, and newcomer services. Taking Better Care of Our Animals: Maple Leaf Foods provided 100% of its owned sow spaces with open sow housing according to the NFACC Code of Practice and Canadian Pork Excellence PigCARE standards. The Company implemented environmental enrichment for pigs and broiler chickens and invested in humane processing technologies, converting 99.9% of its chicken plants to Controlled Atmosphere Stunning. Taking Better Care of Our Planet: By the end of 2024, Maple Leaf Foods achieved a 5.1% reduction in absolute Scope 1 and 2 emissions and a 15.6% reduction in Scope 3 emissions intensity since the 2018 base year. The Company expanded its regenerative agriculture efforts, collaborating with Nutrien for the fourth consecutive year, scaling from 19,000 to over 250,000 acres, to support growers and boost sustainability. It also supported the Lake Winnipeg Basin Water Stewardship Project, engaging 30,000 acres across four farms to implement water stewardship practices on farms. Additionally, the Company achieved a 94.1% company-wide landfill diversion rate, with three facilities reaching 100% landfill diversion. For more information and to view the full 2024 Integrated Report, please visit: Forward–Looking Statements This document contains, and the Company's oral and written public communications often contain, "forward-looking information" within the meaning of applicable securities law. These statements are based on current expectations, estimates, projections, beliefs, judgements and assumptions based on information available at the time the applicable forward-looking statement was made and in light of the Company's experience combined with its perception of historical trends. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. The Company believes the expectations reflected in the forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. For the full statement around forward-looking information, please refer to the 2024 Annual Report to Shareholders. About Maple Leaf Foods Inc. Maple Leaf Foods is a leading protein company responsibly producing food products under leading brands including Maple Leaf ®, Maple Leaf Prime ®, Maple Leaf Natural Selections ®, Schneiders ®, Mina ®, Greenfield Natural Meat Co. ®, LightLife ® and Field Roast ™. The Company employs approximately 13,500 people and does business primarily in Canada, the U.S. and Asia. The Company is headquartered in Mississauga, Ontario and its shares trade on the Toronto Stock Exchange (MFI).
